Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.

Yi Chao FoongDaniel MerloMelissa GresleKatherine BuzzardMichael ZhongWei Zhen YehVilija G JokubaitisMastura MonifOlga SkibinaSerkan OzakbasFrancesco PattiPierre GrammondMaria Pia AmatoTomas KalincikDana HorakovaEva Kubala HavrdovaBianca Weinstock-GuttmanJeanette Lechner ScottCavit BozMaria Jose SaHelmut ButzkuevenAnneke Van Der Walt Chao Zhunull null

Published in: Journal of neurology, neurosurgery, and psychiatry (2024)

In older pwMS, ocrelizumab effectively reduced relapses compared with IFN/GA. Overall relapse activity was low. This study adds valuable real-world data for informed DMT decision making with older pwMS. Our study also confirms that there is a treatment benefit in older people with MS, given the existence of a clear differential treatment effect between ocrelizumab and IFN/GA in the over 60 age group.

Keyphrases

multiple sclerosis
pet ct
dendritic cells
physical activity
decision making
middle aged
community dwelling
mass spectrometry
combination therapy
big data
electronic health record
white matter
artificial intelligence
deep learning
replacement therapy